Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Adrabetadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Biomarker; Therapeutic Use
- 27 Oct 2023 Status changed from active, no longer recruiting to recruiting.
- 29 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.